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endovascular aortic aneurysm repair
William B. Newton III, Mrinal Shukla, Jeanette S. Andrews, Kimberley J.
Hansen, Matthew A. Corriere, Philip P. Goodney, Matthew S. Edwards
Purpose: Outcomes and predictors of acute surgical conversion during endo-
vascular aortic aneurysm repair (EVAR) were examined using the American
College of Surgeons-National Safety and Quality Improvement Project
(ACS-NSQIP) Database (2005 to 2008).
Methods: Acute intraoperative surgical conversions occurring during elective
EVARwere identifiedusingCurrentProcedural Terminologycodes.Nonemergent
EVAR and primary open surgical repairs of infrarenal aneurysms were examined
for comparison. Perioperative morbidity was categorized as wound, pulmonary,
venous thromboembolic, genitourinary, cardiovascular, operative, and septic.
Mortality, overall morbidity, and length of stay (LOS) were examined.
Results:We identified 72 acute conversions, 2414 open repairs, and 6332 EVAR
without acute conversion. Demographics and comorbidities were generally
similar among operative groups. Mean operative time was 274 minutes for
acute conversion vs 226 minutes for primary open repair and 162 minutes for
EVAR (conversion vs EVAR and open repair vs EVAR P< .0001 for each; conver-
sion vs open repair P = .0014; analysis on rank operative time). Blood transfu-
sion was required in 69% of acute conversions (mean volume, 6.0 units) vs 73%
of open repairs (mean volume, 3.3 units) and 12% of EVARs (mean volume, 2.6
units; P < .0001 for each pair-wise comparison; analysis on rank number of
units among those transfused).Majormorbiditywas 28% for acute conversions,
28% for open repairs, and 12% for EVARs. Mortality was 4.2% for acute conver-
sions, 3.2% for open repairs, and 1.3% for EVARs. Median (quartile 1, quartile 3)
LOSwas 7 (5, 9) days for acute conversion and open repair, and 2 (1, 3) days for
EVAR. Morbidity and mortality were significantly higher for acute conversion
and open repair vs EVAR. The OR (95% confidence interval) for morbidity was
2.9 (1.7-4.8) after conversion and 2.8 (2.5-3.2) after open repair (P < .0001
for both) and for mortality was 3.4 (1.0-10.9; P = .0437) for conversion and
2.5 (1.9-3.5; P < .0001) for open repair. Morbidity and mortality were similar
between acute conversion and open repair. A similar pattern among repair
groups was demonstrated for LOS, with similar LOS for acute conversions
and open repair, which were significantly longer than those observed for
EVAR. No significant demographic or medical risk factor predictors of acute
conversion during EVAR were identified.
Conclusion: Acute surgical conversion was a rare complication affecting
1.1% of EVAR cases, with no broadly identifiable at-risk population. When
conversion did occur, morbidity and mortality rates paralleled those
observed for elective open repair.Endovascular therapy for infected aortic aneurysms
Boonprasit Kritpracha, Dhanakom Premprabha, Jitpreedee Sungsiri,
Wittawat Tantarattanapong, Sorracha Rookkapan, Pong Juntarapatin
Objective: To determine the outcome of endovascular therapy for an
infected aortic aneurysm in patients with or without aorto-aerodigestive/
aortocaval fistulas.* Full articles available online at www.jvascsurg.org
1078e5884/$36.00
doi:10.1016/S1078-5884(11)00618-6Methods: From September 2005 to May 2010, 21 patients, 17 abdominal and
four thoracic infected aortic aneurysms were treated with an endovascular
stent graft at Songklanagarind Hospital, Thailand. Five patients presented
with fistula complications, 1 aortoesophageal, 1 aortobronchial, 1 aorto-
caval, and 2 aortoenteric fistulas. Lifelong antibiotics were planned for all
patients. In-hospital mortality and follow-up outcomes were examined.
Results: The average age was 66 years (range, 42-84) and 18 patients were
male. All five cases in the fistulous group presented with symptoms related
to the organs involved, four massive bleedings and one congestive heart
failure. Symptoms of patients in the nonfistulous group were abdominal,
back, or chest pain in 94%, fever in 81%, and diarrhea in 19%. Blood culture
was positive in 10 patients (48%): eight Salmonella spp and two Burkholderia
pseudomallei. The overall in-hospital mortality was 19% (4/21): 60% (3/5) in
the fistula group and only 6% (1/16) in the nonfistula group. One conversion
to open repair was performed in the fistula group 2 weeks after the endovas-
cular procedure. During the follow-up period, one of the two survivors in the
fistula group died at 18 months from unrelated causes, while there were no
deaths in the 15 patients of the nonfistula group with an average patient
follow-up of 22 months (range, 1-54). Periaortic inflammation and aneurysms
in the nonfistula group completely disappeared in 10 of the 15 patients
(67%). The aneurysm significantly shrunk in four patients (27%), and was
stable at 1 month in one patient. There were no late conversions.
Conclusion: Endovascular therapy, as a definite treatment for infected
aortic aneurysms, provided excellent short- and medium-term results in
patients without fistula complications. However, a poorer outcome was
evident in patients with fistula complications.Results of endovascular aortic aneurysm repair with general, regional,
and local/monitored anesthesia care in the American College of
Surgeons National Surgical Quality Improvement Program database
Matthew S. Edwards, Jeanette S. Andrews, Angela F. Edwards, Racheed J.
Ghanami, Matthew A. Corriere, Philip P. Goodney, Christopher J. Godshall,
Kimberley J. Hansen
Background: This study examined outcomes of endovascular repair of
infrarenal abdominal aortic aneurysms (EVAR) using general, spinal,
epidural, and local/monitored anesthesia care (MAC) in a multicenter North
American hospital database reflecting contemporary anesthesia and surgical
practices.
Methods: Elective EVAR cases performed between 2005 and 2008 were iden-
tified from the American College of Surgeons National Surgical Quality
Improvement Program database using Current Procedural Terminology
codes. Excluded were emergency cases and patients with concomitant
procedures requiring general anesthesia. Patient-level comorbidities, char-
acteristics, and intraoperative and postoperative details were examined.
Complications were analyzed individually and in aggregate categories,
including wound, pulmonary, renal, venous thromboembolic, cardiovascular,
operative, and septic. Length of stay (LOS) and 30-day mortality were exam-
ined. Characteristics and outcomes were described using mean  standard
deviation or count (%), and comparisons were evaluated for statistical signif-
icance using c2, Fisher exact test, and univariate linear regression. LOS was
analyzed with linear regression techniques using a log transformation.
714 AbstractsAssociations between anesthesia type and outcomes were examined using
univariable and multivariable regression techniques.
Results: We identified 6009 elective EVAR procedures for analysis. General
anesthesia was used in 4868 cases, spinal anesthesia in 419, epidural anes-
thesia in 331, and local/MAC in 391. Defined morbidity occurred in 11% of
patients. Median LOS was 2 (interquartile range, 1-3) days, and mean LOS
was 2.8  4.3 days. The 30-day mortality rate was 1.1%. Significant multivar-
iate associations were observed between anesthesia type, pulmonary
morbidity, and log-LOS. General anesthesia was associated with an increase
in pulmonary morbidity vs spinal (odds ratio [OR], 4.0; 95% confidence
interval [CI], 1.3-12.5; P = .020) and local/MAC anesthesia (OR, 2.6; 95%
CI, 1.0-6.4; P = .041). Use of general anesthesia was associated with a 10%
increase in LOS for general vs spinal anesthesia (95% CI, 4.8%-15.5%; P =
.001) and a 20% increase for general vs local/MAC anesthesia (95% CI,
14.1%-26.2%; P < .001). Trends toward increased pulmonary morbidity and
LOS were not observed for general vs epidural anesthesia. No significant
association between anesthesia type and mortality was observed.
Conclusions: In contemporary North American anesthetic and surgical prac-
tice, general anesthesia for EVAR was associated with increased postopera-
tive LOS and pulmonary morbidity compared with spinal and local/MAC
anesthesia. These data suggest that increasing the use of less-invasive anes-
thetic techniques may limit postoperative complications and decrease the
overall costs of EVAR.Randomized clinical trial of open-cell vs closed-cell stents for carotid
stenting and effects of stent design on cerebral embolization
Carlos H. Timaran, Eric B. Rosero, Adriana Higuera, Adriana Ilarraza,
J. Gregory Modrall, G. Patrick Clagett
Objective: The effect of stent design on cerebral embolization has not been
established. The purpose of this trial was to contrast the incidence of
subclinical cerebral embolization in high-risk patients undergoing carotid
artery stenting (CAS) with open-cell vs closed-cell stents.
Methods: During an 18-month period, 40 patients were randomized (1:1) to
undergo CAS with open-cell (Acculink, n = 20) or closed-cell stents (Xact, n =
20). A single filter device for embolic protection (Accunet filter) was used.
Transcranial Doppler (TCD)-detected microembolic signals (MES) during
CAS and preprocedural and 24-hour postprocedural diffusion-weighted
magnetic resonance imaging (DW-MRI) were used to determine cerebral
embolization. Univariate and nonparametric analyses were used to assess
associations between stent design and cerebral embolization.
Results: CAS was performed in 17 symptomatic patients (43%) and 23 asymp-
tomatic patients (57%) with a similar number of open-cell and closed-cell
stents (9/8 and 11/12, respectively). The total and poststenting median ipsi-
lateral MES counts detected by TCD were 264 (interquartile range [IQR], 222-
343) and 48 (IQR, 41-66) for open-cell stents and 339 (IQR, 163-408) and 53
(IQR, 23-88) for closed-cell stents, respectively (P > .56). New acute cere-
bral emboli detected with DW-MRI occurred in 53% and 47% of patients
undergoing CAS with open-cell and closed-cell stents, respectively (P =
1.0). The total and ipsilateral median numbers of DW-MRI lesions between
groups were not statistically significantly different (ie, 2 [IQR, 0-4] and 1
[IQR, 0-3] for open-cell stents and 1 [IQR, 0-3] and 1 [IQR, 0-2] for closed
cell-stents, respectively; P > .4). One asymptomatic patient undergoing
CAS with an open-cell stent sustained a minor stroke; the 30-day stroke-
death rate in this series was 2.5%.
Conclusion: Cerebral embolization, as detected by TCD and DW-MRI, occurs
with similar frequency after CAS with open-cell and closed-cell stents. This
randomized trial does not support the superiority of any stent design with
respect to cerebral embolization.Safety and feasibility of a novel transcervical access neuroprotection
system for carotid artery stenting in the PROOF Study
Laszlo Pinter, Marc Ribo, Christopher Loh, Barton Lane, Tracy Roberts, Tony
M. Chou, Ralf R. Kolvenbach
Background: Randomized controlled trials have shown that periprocedural
rates of stroke and death are higher with carotid artery stenting (CAS)
than with carotid endarterectomy (CEA) in the treatment of carotid artery
stenosis. Diffusion-weighted magnetic resonance imaging (DW-MRI) has
shown higher rates of clinically silent new ischemic brain lesions when CAS
is performed as compared with CEA. The Silk Road Medical EmbolicPROtectiOn System: First-In-Man (PROOF) Study is a single-arm first-in-man
study using the MICHI Neuroprotection System (Silk Road Medical Inc, Sunny-
vale, Calif), a novel transcervical access and cerebral embolic protection
system. This system enables stent implantation under controlled blood
flow reversal of the carotid artery, also known as Flow Altered Short Trans-
cervical Carotid Artery Stenting (FAST-CAS).
Methods: Between March 2009 and February 2010, a total of 44 subjects were
enrolled into the study. The primary composite endpoint was major stroke,
myocardial infarction, or death within 30 days. Forty-three patients (97.7%)
completed the study through the 30-day endpoint. One patient was lost to
follow-up. In a subgroup of consecutive subjects, DW-MRI examinations were
performed preprocedure and within 24 to 48 hours after the stent implanta-
tion. Blinded independent neuroradiologists reviewed all DW-MRI studies
and confirmed the absence or presence of new ischemic brain lesions.
Results: All enrolled patients were successfully treated, and no major
adverse events were seen through the follow-up period. Thirty-one subjects
had DW-MRI examinations. Of these, five patients (16%) had evidence of new
ischemic brain lesions but no clinical sequelae. Transient intolerance to
reverse flow was reported in 9% of cases, but in all cases, a stent was
successfully placed, and the intolerance was managed by minimizing the
duration of reverse flow during the procedure.
Conclusion: In this first-in-man experience, FAST-CAS using the MICHI Neuro-
protection System was shown to be a safe and feasible method for carotid
revascularization. DW-MRI findings suggest controlled reverse flow provides
cerebral embolic protection similar to that seen with CEA.Disease progression after initial surgical intervention for Takayasu
arteritis
Sung Wan Ham, S. Ram Kumar, Vincent L. Rowe, Fred A. Weaver
Objective: This study was conducted to determine the incidence of disease
progression and the need for subsequent revascularization procedures in
patients with Takayasu arteritis (TA).
Methods: From 1980 to 2009, all patients with TA who underwent an initial
revascularization procedure for end-organ ischemia were identified. The
incidence of subsequent revascularization in another vascular bed or revi-
sion of the initial procedure was determined.
Results: Forty patients (36 women; mean age, 35) underwent an initial
revascularization procedure. Indications for the initial procedure were
hypertension in 20, renal dysfunction in 9, extremity ischemia in 6, and
stroke/transient ischemic attack in 5. The initial revascularization consisted
of 60 bypass procedures and 4 endovascular interventions. During a mean
follow-up of 6.4 years, progression of TA in another vascular bed or
stenosis/occlusion of the initial revascularization procedure occurred in 16
patients (40%). Five patients with progression required one procedure,
whereas 11 required two or more surgical interventions. Procedures required
were renal in 12, cerebrovascular in 8, extremity in 8, aortic reconstruction
in 5, and mesenteric in 1. Postoperative/30-day morbidity was 14%, and one
operative death occurred. Actuarial survival was 94% at 1 year and 85% at 5
years after the remedial procedure.
Conclusions: TA progression is common in patients who require revascular-
ization for end-organ ischemia. This finding emphasizes the need for global
lifelong vascular surveillance of all patients who undergo surgical interven-
tion for TA. The effect of steroid and immunosuppressive therapy on
reducing reoperation requires further study.Predictors of wound complications following major amputation for
critical limb ischemia
Ravishankar Hasanadka, Robert B. McLafferty, Colleen J. Moore, Douglas B.
Hood, Don E. Ramsey, Kim J. Hodgson
Objectives: For patients with end-stage critical limb ischemia (CLI) who
have already suffered over an extended period of time, a major amputation
that is free of wound complications remains paramount. Utilizing data from
the American College of Surgeons, National Surgical Quality Improvement
Program (ACS-NSQIP), the objective of this report was to determine critical
factors leading to wound complications following major amputation.
Methods: ACS-NSQIP was used to identify patients 50 years, with CLI, and
having an ipsilateral below-(BKA) or above-knee amputation (AKA). The
primary outcome was wound occurrence (WO) defined by affirmative find-
ings of superficial infection, deep infection, and/or wound disruption. The
Abstracts 715secondary outcome was 30-day mortality. Following univariate analyses,
a multiple logistic regression was performed to identify predictive factors.
Results: Between January 1, 2005 and December 31, 2008, 4250 patients ful-
filled inclusion criteria (2309 BKAs and 1941 AKAs). WOs were 10.4% for BKAs
and 7.2% for AKAs. For BKAs, increasing elevation in international normalized
ratio (INR) predicted more WOs (P = .008, odds ratio [OR] 1.5 for every inte-
gral increase in INR) as did age 50 to 59 compared with older patients (P =
.002, OR 1.9). For AKAs, being a current smoker predicted more WOs (P =
.0008, OR 1.8) as did an increasing body mass index (BMI) (P = .02, OR 1.3
for every 10 kg/m2 increase in BMI). Mortality was 7.6% for BKAs and 12%
for AKAs. Complete functional dependence was most predictive of mortality
following AKA (P < .0001, OR 2.5). Medical comorbidities such as history of
myocardial infarcation (MI) (OR 1.8), congestive heart failure (CHF, OR
1.6), and chronic obstructive pulmonary disease (COPD, OR 1.6) predicted
mortality following BKA, while dialysis use (OR 2.4), CHF (OR 2.3), and
COPD (OR 2.1) predicted mortality following AKA.
Conclusions: Wound occurrences and mortality rates after major amputa-
tion for CLI continue to be a prevalent problem. Normalization of the INR
prior to BKA should decrease WOs. Heightened awareness in higher risk
patients with improved preventive measures, earlier disease recognition,
better treatments, and increased education remain critical to improving
outcomes in an already stressed patient cohort.Predictors of outcome for renal artery stenting performed for salvage of
renal function
J. Gregory Modrall, Carlos H. Timaran, Eric B. Rosero, Jayer Chung, Frank A.
Arko III, R. James Valentine, G. Patrick Clagett, Clayton Trimmer
Objective: To identify preoperative clinical features that predict a durable
improvement in renal function with renal artery stenting (RAS).Methods: Sixty-one patients with renal insufficiency (serum creatinine 1.5
mg/dL) underwent RAS for renal salvage. Patients were categorized as
“responders” if estimated glomerular filtration rate (eGFR) at last follow-
up was improved 20% or more over baseline. Patients with stable or worse
renal function after RAS were labeled “non-responders.” For the purpose
of calculating changes in eGFR, patients on dialysis were represented by
an eGFR of 10 ml/min/1.73 m2. Renal volume was estimated as kidney length
 width  depth/2.
Results: The median age of the cohort was 66 years (interquartile range
[IQR], 60-73 years). Median preoperative serum creatinine was 1.8 mg/dL
(IQR, 1.6-2.3), and median estimated glomerular filtration rate (eGFR) was
34 mL/min/1.73 m2 (IQR, 24-45). With stenting, 17 of 61 patients (27.9%)
derived a durable improvement in renal function at a median follow-up of
24 months (IQR, 16-33 months). The largest proportion of stented patients
(44.3%) had no improvement in renal function after stenting, while a subset
(27.9%) experienced a decline in renal function. Responders enjoyed a 47%
improvement in renal function from baseline, while non-responders had
a 13% decrement in renal function (P < .0001). Responders had a higher
baseline serum creatinine, lower eGFR, and a steeper decline in renal func-
tion prior to RAS, compared with non-responders. Kidney length, width,
depth, and volume were not significantly different between responders
and non-responders. Logistic regression analysis identified the rate of
decline of renal function prior to stenting as the only independent preoper-
ative predictor of improved renal function after RAS (odds ratio, 3.4; 95%
confidence interval, 1.6 to 7.5; P = .0019). The rate of decline in eGFR per
week was more than 20-fold greater for responders than non-responders
(2.1% vs 0% decline in eGFR per week; P < .0001). No predictors of renal
function deterioration after stenting were identified.
Conclusions: The current study found that a steep decline in preoperative
renal function portends a higher likelihood of renal salvage from RAS among
patients with renal insufficiency. Incorporating this finding into patient
selection may improve outcomes for RAS.
